Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors

Published:2018-09 Issue:5 Volume:19 Page:e655-e665
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Camidge D. Ross,Sequist Lecia V.,Jänne Pasi A.,Weickhardt Andrew J.,Dowling Elizabeth S.,Alicea Jeanette,Fan Jean,Oxnard Geoffrey R.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference40 articles.

1. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

2. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

5. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J Clin Oncol,2013

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?;Expert Review of Anticancer Therapy;2022-11-24

2. Principles of Dose, Schedule, and Combination Therapy;Holland‐Frei Cancer Medicine;2022-10-21

3. High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience;JTO Clinical and Research Reports;2022-06

4. Optimizing the future: how mathematical models inform treatment schedules for cancer;Trends in Cancer;2022-06

5. The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer;Expert Opinion on Drug Discovery;2021-06-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3